A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
A phase 3 trial testing DZD8586 in chronic lymphocytic leukaemia, now recruiting.
Overview
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) is a phase 3 interventional study registered as NCT07139873, led by Dizal Pharmaceuticals, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Open-Label, Randomised, Multicenter Study to Evaluate Anti-tumour Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Planned enrolment is 250 participants (estimated). The study started in 2025-09-08 and primary completion is expected in 2029-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TrialStudy of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TrialICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentCTX112
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentBexobrutideg
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentICP-248
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentKRT-232
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentRocbrutinib
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.